Supercharged immune cells take aim at Virus-Linked cancer
NCT ID NCT02065362
Summary
This early-stage study is testing a new type of cell therapy for patients with EBV-positive nasopharyngeal cancer that has returned or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer cells infected with the Epstein-Barr virus (EBV), and then infuse them back into the patient. The main goal is to see if these specially engineered immune cells are safe and how long they last in the body to potentially control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-POSITIVE NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.